Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1987 1
1993 3
1994 2
1996 1
1997 1
1998 2
1999 4
2000 2
2001 5
2002 1
2003 2
2004 1
2005 5
2006 11
2007 10
2008 13
2009 12
2010 15
2011 11
2012 28
2013 25
2014 34
2015 27
2016 49
2017 29
2018 44
2019 57
2020 72
2021 83
2022 80
2023 85
2024 38

Text availability

Article attribute

Article type

Publication date

Search Results

669 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH; ESCORT-1st Investigators. Luo H, et al. Among authors: ba y. JAMA. 2021 Sep 14;326(10):916-925. doi: 10.1001/jama.2021.12836. JAMA. 2021. PMID: 34519801 Free PMC article. Clinical Trial.
Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy.
Long H, Jia Q, Wang L, Fang W, Wang Z, Jiang T, Zhou F, Jin Z, Huang J, Zhou L, Hu C, Wang X, Zhang J, Ba Y, Gong Y, Zeng X, Zeng D, Su X, Alexander PB, Wang L, Wang L, Wan YY, Wang XF, Zhang L, Li QJ, Zhu B. Long H, et al. Among authors: ba y. Cancer Cell. 2022 Jun 13;40(6):674-693.e7. doi: 10.1016/j.ccell.2022.04.018. Epub 2022 May 19. Cancer Cell. 2022. PMID: 35594863 Free article.
Nutritional assessment and risk factors associated to malnutrition in patients with esophageal cancer.
Cao J, Xu H, Li W, Guo Z, Lin Y, Shi Y, Hu W, Ba Y, Li S, Li Z, Wang K, Wu J, He Y, Yang J, Xie C, Zhou F, Song X, Chen G, Ma W, Luo S, Chen Z, Cong M, Ma H, Zhou C, Wang W, Qi Luo, Shi Y, Qi Y, Jiang H, Guan W, Chen J, Chen J, Fang Y, Zhou L, Feng Y, Tan R, Ou J, Zhao Q, Wu J, Xin Lin, Yang L, Fu Z, Wang C, Deng L, Li T, Song C, Shi H; Investigation on Nutrition Status and Clinical Outcome of Common Cancers (INSCOC) Group, Chinese Society of Nutritional Oncology. Cao J, et al. Among authors: ba y. Curr Probl Cancer. 2021 Feb;45(1):100638. doi: 10.1016/j.currproblcancer.2020.100638. Epub 2020 Aug 14. Curr Probl Cancer. 2021. PMID: 32829957 Review.
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.
Liu T, Bai Y, Lin X, Li W, Wang J, Zhang X, Pan H, Bai C, Bai L, Cheng Y, Zhang J, Zhong H, Ba Y, Hu W, Xu R, Guo W, Qin S, Yang N, Lu J, Shitara K, Lei M, Li M, Bao N, Chen T, Shen L. Liu T, et al. Among authors: ba y. Int J Cancer. 2023 Feb 15;152(4):749-760. doi: 10.1002/ijc.34296. Epub 2022 Oct 31. Int J Cancer. 2023. PMID: 36121651 Free PMC article. Clinical Trial.
Associations Between Life's Essential 8 and Chronic Kidney Disease.
Ren Y, Cai Z, Guo C, Zhang Y, Xu H, Liu L, Wang L, Ba Y, Liu S, Zhang G, Liu Z, Han X. Ren Y, et al. Among authors: ba y. J Am Heart Assoc. 2023 Dec 19;12(24):e030564. doi: 10.1161/JAHA.123.030564. Epub 2023 Dec 8. J Am Heart Assoc. 2023. PMID: 38063194 Free PMC article.
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors.
Zhao Y, Ma Y, Zang A, Cheng Y, Zhang Y, Wang X, Chen Z, Qu S, He J, Chen C, Jin C, Zhu D, Li Q, Liu X, Su W, Ba Y, Hao Y, Chen J, Zhang G, Qu S, Li Y, Feng W, Yang M, Liu B, Ouyang W, Liang J, Yu Z, Kang X, Xue S, Yang G, Yan W, Yang Y, Liu Z, Peng Y, Fanslow B, Huang X, Zhang L, Zhao H. Zhao Y, et al. Among authors: ba y. J Hematol Oncol. 2023 May 8;16(1):50. doi: 10.1186/s13045-023-01445-1. J Hematol Oncol. 2023. PMID: 37158938 Free PMC article. Clinical Trial.
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
Xu RH, Zhang Y, Pan H, Feng J, Zhang T, Liu T, Qin Y, Qin S, Yin X, Liu B, Ba Y, Yang N, Voon PJ, Tanasanvimon S, Zhou C, Zhang WL, Shen L. Xu RH, et al. Among authors: ba y. Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1015-1024. doi: 10.1016/S2468-1253(21)00313-7. Epub 2021 Oct 7. Lancet Gastroenterol Hepatol. 2021. PMID: 34626550 Clinical Trial.
669 results